Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Stopped early · Phase 2
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Biological therapies, such as anti-thymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Anti-thymocyte globulin may also make cancer cells more sensitive to melphalan. Giving anti-thymocyte globulin together with melphalan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together with melphalan works in treating patients with relapsed multiple myeloma.
Key facts
- Study ID
- NCT00635024
- Run by
- Mayo Clinic
- People needed
- 1
- Starts
- 2008-05-01
- Expected to finish
- 2010-11-01
- Last updated by the study team
- 2017-02-10
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.